Latest News: Treatments & Research
19 July 2019 / Posted in: Treatments & Research
The conference will be held at Génocentre in Evry, south of Paris between 5th & 7th February 2020 and is open for healthcare professionals and researchers in SMA to attend. The congress will feature a series of talks and workshops covering key scientific and clinical research fields in SMA.
10 July 2019 / Posted in: Treatments & Research
We have received this reply in response to the letter sent by SMA UK, MDUK and TreatSMA on 14th June 2019.
03 July 2019 / Posted in: Treatments & Research
The MAA for nusinersen (Spinraza) will now include paediatric patients who have recently (in the previous 12 months) lost the ability to walk independently. It also commits to considering any significant evidence being made available by Biogen in relation to all with SMA Type 3 who are non-ambulant, that may impact on the eligibility criteria of the MAA. These are just two changes following many confidential discussions which we have been unable to report on until now.
02 July 2019 / Posted in: Treatments & Research
Following recent communication from the Scottish Government, the Scottish Medicines Consortium webpage for nusinersen has been updated to advise that, as well as being available for those with SMA Type 1, from July 2019 nusinersen can be prescribed for those with SMA Types 2 and 3.
26 June 2019 / Posted in: Treatments & Research
The SoC is now available via the TREAT-NMD website. It describes what assessments and interventions families and adults should expect to find in any neuromuscular centre anywhere.
25 June 2019 / Posted in: Treatments & Research
Patient groups would like to find out what you think about this new treatment so that we can include your views in our submissions to the National Institute for Health and Care Excellence (NICE). Our survey closes on 21st July 2019.
20 June 2019 / Posted in: Treatments & Research
We are so sorry to hear of the continued heightened distress in the SMA Community caused by NICE / NHS England’s decisions and communications to date. We are doing all we can to obtain a reply to the letter sent by clinicians and the patient groups on 14th June. This was sent following consultation, advice and a joint decision that this step was the most promising way to obtain a change to the MAA.
Patient Advocacy Groups and Clinicians write to NICE & NHSE about the nusinersen MAA and the impact this has had on the SMA Community
14 June 2019 / Posted in: Treatments & Research
Today we have co-signed two letters to address the concerns that are being widely expressed about the nusinersen Managed Access Agreement (MAA).
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
11 June 2019 / Posted in: Treatments & Research
Scholar Rock announced that SRK-015 was well-tolerated in healthy volunteers across all tested doses and shows robust and durable target engagement, supporting evaluation in the Phase 2 trial in SMA, which is currently ongoing.
10 June 2019 / Posted in: Treatments & Research
Following an application by AveXis, NICE is progressing an appraisal of this treatment to see if it will recommend it for provision by NHS England for the treatment of infants with SMA Type 1. We will be asking the Community for their views and making a submission by the deadline of 31st July.